1
|
Bagaria DK, Gupta S, Pandey S, Choudhary N, Priyadarshini P, Kumar A, Alam J, Mishra B, Sagar S, Kumar S, Gupta A. Abdominal wall reconstruction (AWR) for post-trauma laparotomy ventral hernia and follow-up assessment of functional quality of life (QOL): experience of a level-1 trauma centre in India. Hernia 2024:10.1007/s10029-024-02978-1. [PMID: 38388814 DOI: 10.1007/s10029-024-02978-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Accepted: 01/25/2024] [Indexed: 02/24/2024]
Abstract
PURPOSE The aim of this study was to examine the postoperative outcomes and follow-up QOL of patients after AWR at a level-1 trauma centre in India. METHODS The study cohort included AWR patients treated between January 2011 and July 2022. The Activities Assessment Scale (AAS) was used to measure QOL, and the Ventral Hernia Recurrence Inventory (VHRI) was used to determine the occurrence of recurrence. In patients suspected of having recurrence, thorough clinical examination and relevant imaging were performed to confirm or rule out recurrence. RESULTS Out of 89 patients, 35 patients whose complete perioperative and follow-up data were available were enrolled. The mean age of the patients was 28 (SD, 9) years. The mean defect size was 14. 9 (SD, 7) cm. The mean time from laparotomy to AWR surgery was 21 months. During the postoperative course, 37% of patients developed complications, such as SSI and seroma. The mean follow-up time was 53 (SD, 43) months. Upon comparing procedures involving the mesh placed in the sublay position with procedures involving the mesh placed in other positions, no statistically significant difference in the recurrence rate (one in each group, p = 0.99), surgical complication rate (33% v/s 66%, p = 0.6), or mean AAS QOL score (94.7 v/s 98, p = 0.4) was observed. The specificity of the VHRI for diagnosing recurrence was 79%. CONCLUSION Overall, the recurrence rate was low in these patients despite the presence of large hernia defects. Long-term QOL was not affected by the specific procedure used. Timely planning and execution are more important than the specific repair approach for post-trauma laparotomy ventral hernia.
Collapse
Affiliation(s)
- D K Bagaria
- Division of Trauma Surgery and Critical Care, Jai Prakash Narayan Apex Trauma Centre, Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
| | - S Gupta
- Division of Trauma Surgery and Critical Care, Jai Prakash Narayan Apex Trauma Centre, Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
| | - S Pandey
- Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India
| | - N Choudhary
- Division of Trauma Surgery and Critical Care, Jai Prakash Narayan Apex Trauma Centre, Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India.
| | - P Priyadarshini
- Division of Trauma Surgery and Critical Care, Jai Prakash Narayan Apex Trauma Centre, Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
| | - A Kumar
- Division of Trauma Surgery and Critical Care, Jai Prakash Narayan Apex Trauma Centre, Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
| | - J Alam
- Division of Trauma Surgery and Critical Care, Jai Prakash Narayan Apex Trauma Centre, Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
| | - B Mishra
- Division of Trauma Surgery and Critical Care, Jai Prakash Narayan Apex Trauma Centre, Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
| | - S Sagar
- Division of Trauma Surgery and Critical Care, Jai Prakash Narayan Apex Trauma Centre, Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
| | - S Kumar
- Division of Trauma Surgery and Critical Care, Jai Prakash Narayan Apex Trauma Centre, Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
| | - A Gupta
- Division of Trauma Surgery and Critical Care, Jai Prakash Narayan Apex Trauma Centre, Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
| |
Collapse
|
2
|
Fjeld K, Gravdal A, Brekke RS, Alam J, Wilhelm SJ, El Jellas K, Pettersen HN, Lin J, Solheim MH, Steine SJ, Johansson BB, Njølstad PR, Verbeke CS, Xiao X, Lowe ME, Molven A. The genetic risk factor CEL-HYB1 causes proteotoxicity and chronic pancreatitis in mice. Pancreatology 2022; 22:1099-1111. [PMID: 36379850 DOI: 10.1016/j.pan.2022.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 10/31/2022] [Accepted: 11/04/2022] [Indexed: 11/11/2022]
Abstract
BACKGROUND & AIMS The CEL gene encodes the digestive enzyme carboxyl ester lipase. CEL-HYB1, a hybrid allele of CEL and its adjacent pseudogene CELP, is a genetic variant suggested to increase the risk of chronic pancreatitis (CP). Our aim was to develop a mouse model for CEL-HYB1 that enables studies of pancreatic disease mechanisms. METHODS We established a knock-in mouse strain where the variable number of tandem repeat (VNTR) region of the endogenous mouse Cel gene was substituted with the mutated VNTR of the human CEL-HYB1 allele. Heterozygous and homozygous Cel-HYB1 mice and littermate wildtype controls were characterized with respect to pancreatic pathology and function. RESULTS We successfully constructed a mouse model with pancreatic expression of a humanized CEL-HYB1 protein. The Cel-HYB1 mice spontaneously developed features of CP including inflammation, acinar atrophy and fatty replacement, and the phenotype became more pronounced as the animals aged. Moreover, Cel-HYB1 mice were normoglycemic at age 6 months, whereas at 12 months they exhibited impaired glucose tolerance. Immunostaining of pancreatic tissue indicated the formation of CEL protein aggregates, and electron microscopy showed dilated endoplasmic reticulum. Upregulation of the stress marker BiP/GRP78 was seen in pancreatic parenchyma obtained both from Cel-HYB1 animals and from a human CEL-HYB1 carrier. CONCLUSIONS We have developed a new mouse model for CP that confirms the pathogenicity of the human CEL-HYB1 variant. Our findings place CEL-HYB1 in the group of genes that increase CP risk through protein misfolding-dependent pathways.
Collapse
Affiliation(s)
- Karianne Fjeld
- The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway; Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway.
| | - Anny Gravdal
- The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway; Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway
| | - Ranveig S Brekke
- The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway; Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway
| | - Jahedul Alam
- The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway
| | - Steven J Wilhelm
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - Khadija El Jellas
- The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway
| | - Helene N Pettersen
- The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway
| | - Jianguo Lin
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - Marie H Solheim
- Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway
| | - Solrun J Steine
- The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Bente B Johansson
- Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway
| | - Pål R Njølstad
- Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway; Pediatric and Youth Clinic, Haukeland University Hospital, Bergen, Norway
| | - Caroline S Verbeke
- Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Department of Pathology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Xunjun Xiao
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - Mark E Lowe
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - Anders Molven
- The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Department of Pathology, Haukeland University Hospital, Bergen, Norway; Section for Cancer Genomics, Haukeland University Hospital, Bergen, Norway
| |
Collapse
|
3
|
Romaine A, Melleby AO, Alam J, Lobert VH, Lu N, Lockwood FE, Hasic A, Lunde IG, Sjaastad I, Stenmark H, Herum KM, Gullberg D, Christensen G. Integrin α11β1 and syndecan-4 dual receptor ablation attenuates cardiac hypertrophy in the pressure overloaded heart. Am J Physiol Heart Circ Physiol 2022; 322:H1057-H1071. [PMID: 35522553 DOI: 10.1152/ajpheart.00635.2021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Pathological myocardial hypertrophy in response to an increase in left ventricular (LV) afterload may ultimately lead to heart failure. Cell surface receptors bridge the interface between the cell and the ECM in cardiac myocytes and cardiac fibroblasts, and have been suggested to be important mediators of pathological myocardial hypertrophy. We identify for the first time that integrin α11 (α11) is preferentially upregulated amongst integrin beta 1 heterodimer-forming α subunits in response to increased afterload induced by aortic banding (AB) in wild type mice (WT). Mice were anesthetized in a chamber with 4% isoflurane and 95% oxygen before being intubated and ventilated with 2.5% isoflurane and 97% oxygen. For pre- and post-operative analgesia, animals were administered 0.02 mL buprenorphine (0.3 mg/mL) subcutaneously. Surprisingly, mice lacking α11 develop myocardial hypertrophy following AB comparable to WT. In the mice lacking α11, we further show a compensatory increase in the expression of another mechanoreceptor, syndecan-4, following AB compared to WT AB mice, indicating that syndecan-4 compensated for lack of α11. Intriguingly, mice lacking mechanoreceptors α11 and syndecan-4 show ablated myocardial hypertrophy following AB compared to WT mice. Expression of the main cardiac collagen isoforms col1a2 and col3a1 was significantly reduced in AB mice lacking mechanoreceptors α11 and syndecan-4 compared to WT AB.
Collapse
Affiliation(s)
- Andreas Romaine
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.,KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway and Center for Heart Failure Research, Oslo University Hospital, Oslo, Norway
| | - Arne Olav Melleby
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.,KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway and Center for Heart Failure Research, Oslo University Hospital, Oslo, Norway.,Section of Physiology, Department of Molecular Medicine, Institute for Basic Medical Sciences, University of Oslo, Oslo, Norway
| | - Jahedul Alam
- Department of Biomedicine, University of Bergen, Bergen, Norway
| | | | - Ning Lu
- Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Francesca E Lockwood
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.,KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway and Center for Heart Failure Research, Oslo University Hospital, Oslo, Norway
| | - Almira Hasic
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.,KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway and Center for Heart Failure Research, Oslo University Hospital, Oslo, Norway
| | - Ida G Lunde
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.,KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway and Center for Heart Failure Research, Oslo University Hospital, Oslo, Norway
| | - Ivar Sjaastad
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.,KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway and Center for Heart Failure Research, Oslo University Hospital, Oslo, Norway
| | - Harald Stenmark
- Institute for Cancer Research, Oslo University Hospital, Norway
| | - Kate M Herum
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.,KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway and Center for Heart Failure Research, Oslo University Hospital, Oslo, Norway.,Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark
| | - Donald Gullberg
- Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Geir Christensen
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.,KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway and Center for Heart Failure Research, Oslo University Hospital, Oslo, Norway
| |
Collapse
|
4
|
Kahraman S, Dirice E, Basile G, Diegisser D, Alam J, Johansson BB, Gupta MK, Hu J, Huang L, Soh CL, Huangfu D, Muthuswamy SK, Raeder H, Molven A, Kulkarni RN. Abnormal exocrine-endocrine cell cross-talk promotes β-cell dysfunction and loss in MODY8. Nat Metab 2022; 4:76-89. [PMID: 35058633 DOI: 10.1038/s42255-021-00516-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Accepted: 12/08/2021] [Indexed: 12/12/2022]
Abstract
MODY8 (maturity-onset diabetes of the young, type 8) is a dominantly inherited monogenic form of diabetes associated with mutations in the carboxyl ester lipase (CEL) gene expressed by pancreatic acinar cells. MODY8 patients develop childhood-onset exocrine pancreas dysfunction followed by diabetes during adulthood. However, it is unclear how CEL mutations cause diabetes. In the present study, we report the transfer of CEL proteins from acinar cells to β-cells as a form of cross-talk between exocrine and endocrine cells. Human β-cells show a relatively higher propensity for internalizing the mutant versus the wild-type CEL protein. After internalization, the mutant protein forms stable intracellular aggregates leading to β-cell secretory dysfunction. Analysis of pancreas sections from a MODY8 patient reveals the presence of CEL protein in the few extant β-cells. The present study provides compelling evidence for the mechanism by which a mutant gene expressed specifically in acinar cells promotes dysfunction and loss of β-cells to cause diabetes.
Collapse
Affiliation(s)
- Sevim Kahraman
- Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, MA, USA
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Harvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA
| | - Ercument Dirice
- Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, MA, USA
- Department of Pharmacology, New York Medical College of Medicine, Valhalla, NY, USA
| | - Giorgio Basile
- Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, MA, USA
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Harvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA
| | - Danielle Diegisser
- Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, MA, USA
- Department of Pharmacology, New York Medical College of Medicine, Valhalla, NY, USA
| | - Jahedul Alam
- Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Bente B Johansson
- Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Manoj K Gupta
- Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, MA, USA
| | - Jiang Hu
- Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, MA, USA
| | - Ling Huang
- Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Chew-Li Soh
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Danwei Huangfu
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Senthil K Muthuswamy
- Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Helge Raeder
- Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway
- Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
| | - Anders Molven
- Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway
- Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Rohit N Kulkarni
- Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, MA, USA.
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Harvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
5
|
Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, Salloway S, Sampaio C, Sims JR, Sperling B, Sperling R, Welsh-Bohmer KA, Touchon J, Vellas B, Aisen P. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force. J Prev Alzheimers Dis 2020; 6:164-168. [PMID: 31062826 DOI: 10.14283/jpad.2019.12] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Combination therapy is expected to play an important role for the treatment of Alzheimer's disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer's Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.
Collapse
Affiliation(s)
- S Gauthier
- Serge Gauthier, McGill Center for Studies in Aging, Verdun QC, Canada,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Alam J, Musiime M, Romaine A, Sawant M, Melleby AO, Lu N, Eckes B, Christensen G, Gullberg D. Generation of a novel mouse strain with fibroblast-specific expression of Cre recombinase. Matrix Biol Plus 2020; 8:100045. [PMID: 33543038 PMCID: PMC7852330 DOI: 10.1016/j.mbplus.2020.100045] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 06/30/2020] [Accepted: 06/30/2020] [Indexed: 01/06/2023] Open
Abstract
Cell-specific expression of genes offers the possibility to use their promoters to drive expression of Cre-recombinase, thereby allowing for detailed expression analysis using reporter gene systems, cell lineage tracing, conditional gene deletion, and cell ablation. In this context, current data suggest that the integrin α11 subunit has the potential to serve as a fibroblast biomarker in tissue regeneration and pathology, in particular in wound healing and in tissue- and tumor fibrosis. The mesenchyme-restricted expression pattern of integrin α11 thus prompted us to generate a novel ITGA11-driver Cre mouse strain using a ϕC31 integrase-mediated knock-in approach. In this transgenic mouse, the Cre recombinase is driven by regulatory promoter elements within the 3 kb segment of the human ITGA11 gene. β-Galactosidase staining of embryonic tissues obtained from a transgenic ITGA11-Cre mouse line crossed with Rosa 26R reporter mice (ITGA11-Cre;R26R) revealed ITGA11-driven Cre expression and activity in mesenchymal cells in a variety of mesenchymal tissues in a pattern reminiscent of endogenous α11 protein expression in mouse embryos. Interestingly, X-gal staining of mouse embryonic fibroblasts (MEFs) isolated from the ITGA11-Cre;R26R mice indicated heterogeneity in the MEF population. ITGA11-driven Cre activity was shown in approximately 60% of the MEFs, suggesting that the expression of integrin α11 could be exploited for isolation of different fibroblast populations. ITGA11-driven Cre expression was found to be low in adult mouse tissues but was induced in granulation tissue of excisional wounds and in fibrotic hearts following aortic banding. We predict that the ITGA11-Cre transgenic mouse strain described in this report will be a useful tool in matrix research for the deletion of genes in subsets of fibroblasts in the developing mouse and for determining the function of subsets of pro-fibrotic fibroblasts in tissue fibrosis and in different subsets of cancer-associated fibroblasts in the tumor microenvironment. A mouse strain with Cre-recombinase driven by the human integrin α11 promoter has been generated. Cre-recombinase expression in this strain has been characterized using the Rosa26R reporter mouse. ITGA11-Cre is restricted to fibroblast subsets in mouse embryos, skin wounds and fibrotic hearts. This Cre-driver strain will be a useful tool to study role fibroblasts in fibrosis and tumors.
Collapse
Affiliation(s)
- Jahedul Alam
- Department of Biomedicine and Center of Cancer Biomarkers, University of Bergen, Bergen, Norway
| | - Moses Musiime
- Department of Biomedicine and Center of Cancer Biomarkers, University of Bergen, Bergen, Norway
| | - Andreas Romaine
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway
- KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway
- Center for Heart Failure Research, Oslo University Hospital, Oslo, Norway
| | - Mugdha Sawant
- Translational Matrix Biology, University of Cologne Medical Faculty, Cologne, Germany
| | - Arne Olav Melleby
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway
- KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway
- Center for Heart Failure Research, Oslo University Hospital, Oslo, Norway
| | - Ning Lu
- Department of Biomedicine and Center of Cancer Biomarkers, University of Bergen, Bergen, Norway
| | - Beate Eckes
- Translational Matrix Biology, University of Cologne Medical Faculty, Cologne, Germany
| | - Geir Christensen
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway
- KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway
- Center for Heart Failure Research, Oslo University Hospital, Oslo, Norway
| | - Donald Gullberg
- Department of Biomedicine and Center of Cancer Biomarkers, University of Bergen, Bergen, Norway
- Corresponding author Department of Biomedicine and Center of Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, N-5009 Bergen, Norway.
| |
Collapse
|
7
|
Erusappan P, Alam J, Lu N, Zeltz C, Gullberg D. Integrin α11 cytoplasmic tail is required for FAK activation to initiate 3D cell invasion and ERK-mediated cell proliferation. Sci Rep 2019; 9:15283. [PMID: 31653900 PMCID: PMC6814791 DOI: 10.1038/s41598-019-51689-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Accepted: 09/10/2019] [Indexed: 12/31/2022] Open
Abstract
Integrin α11β1 is a collagen-binding integrin, which is receiving increasing attention in the context of wound healing and fibrosis. Although α11β1 integrin displays similar collagen specificity to α2β1 integrin, both integrins have distinct in vivo functions. In this context, the contribution of α11 subunit cytoplasmic tail interactions to diverse molecular signals and biological functions is largely unknown. In the current study, we have deleted the α11 cytoplasmic tail and studied the effect of this deletion on α11 integrin function. Compared to wild-type cells, C2C12 cells expressing tail-less α11 attached normally to collagen I, but formed fewer focal contacts. α11-tail-less cells furthermore displayed a reduced capacity to invade and reorganize a 3D collagen matrix and to proliferate. Analysis of cell signaling showed that FAK and ERK phosphorylation was reduced in cells expressing tail-less α11. Inhibition of ERK and FAK activation decreased α11-mediated cell proliferation, whereas α11-mediated cell invasion was FAK-dependent and occurred independently of ERK signaling. In summary, our data demonstrate that the integrin α11 cytoplasmic tail plays a central role in α11 integrin-specific functions, including FAK-dependent ERK activation to promote cell proliferation.
Collapse
Affiliation(s)
- Pugazendhi Erusappan
- Department of Biomedicine and Center of Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, N-5009, Bergen, Norway.,Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Kirkeveien 166, 0450, Oslo, Norway
| | - Jahedul Alam
- Department of Biomedicine and Center of Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, N-5009, Bergen, Norway
| | - Ning Lu
- Department of Biomedicine and Center of Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, N-5009, Bergen, Norway
| | - Cédric Zeltz
- Department of Biomedicine and Center of Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, N-5009, Bergen, Norway.,Princess Margaret Cancer Center, University Health Network, 101 College Street, Toronto, ON, M5G 1L7, Canada
| | - Donald Gullberg
- Department of Biomedicine and Center of Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, N-5009, Bergen, Norway.
| |
Collapse
|
8
|
Zeltz C, Primac I, Erusappan P, Alam J, Noel A, Gullberg D. Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins. Semin Cancer Biol 2019; 62:166-181. [PMID: 31415910 DOI: 10.1016/j.semcancer.2019.08.004] [Citation(s) in RCA: 163] [Impact Index Per Article: 32.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 08/01/2019] [Accepted: 08/05/2019] [Indexed: 02/06/2023]
Abstract
The tumor microenvironment (TME) is a complex meshwork of extracellular matrix (ECM) macromolecules filled with a collection of cells including cancer-associated fibroblasts (CAFs), blood vessel associated smooth muscle cells, pericytes, endothelial cells, mesenchymal stem cells and a variety of immune cells. In tumors the homeostasis governing ECM synthesis and turnover is disturbed resulting in abnormal blood vessel formation and excessive fibrillar collagen accumulations of varying stiffness and organization. The disturbed ECM homeostasis opens up for new types of paracrine, cell-cell and cell-ECM interactions with large consequences for tumor growth, angiogenesis, metastasis, immune suppression and resistance to treatments. As a main producer of ECM and paracrine signals the CAF is a central cell type in these events. Whereas the paracrine signaling has been extensively studied in the context of tumor-stroma interactions, the nature of the numerous integrin-mediated cell-ECM interactions occurring in the TME remains understudied. In this review we will discuss and dissect the role of known and potential CAF interactions in the TME, during both tumorigenesis and chemoresistance-induced events, with a special focus on the "interaction landscape" in desmoplastic breast, lung and pancreatic cancers. As an example of the multifaceted mode of action of the stromal collagen receptor integrin α11β1, we will summarize our current understanding on the role of this CAF-expressed integrin in these three tumor types.
Collapse
Affiliation(s)
- Cédric Zeltz
- Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway; Princess Margaret Cancer Center, University Health Network, Toronto, Canada
| | - Irina Primac
- Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liege (ULiège), Liege, Belgium
| | - Pugazendhi Erusappan
- Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway
| | - Jahedul Alam
- Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway
| | - Agnes Noel
- Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liege (ULiège), Liege, Belgium
| | - Donald Gullberg
- Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.
| |
Collapse
|
9
|
Ghimire M, Bhoyate S, Gupta RK, Shen X, Perez F, Alam J, Mishra SR. Physical Properties and Theoretical Study of Ni xCo 3-xO₄ (0 ≤ x ≤ 1.5) Nanostructures as High-Performance Electrode Materials for Supercapacitors. J Nanosci Nanotechnol 2019; 19:4481-4494. [PMID: 30913739 DOI: 10.1166/jnn.2019.16644] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Study evaluates the electrochemical performance of off-stoichiometric NixCo3-xO₄ compounds. The off-stoichiometric samples were prepared via hydrothermal technique by systematically varying Co/Ni molar ratio. Physical and electrochemical properties of NixCo3-xO₄ were observed to be stoichiometry dependent. The increase in Ni/Co ratio in NixCo3-xO₄ leads to the morphological transformation from fibrous bundles to urchin like nanospheres with a concomitant increase in the surface area reaching up to 132 m2/g. The optimal specific capacitance of 225 F/g at a current density of 1 A/g and 524 F/g at 10 mV/s scan rate was observed of x 1.0 sample, with an increased retention capacity ∼120% measured at 2 A/g current density. The hybrid density functional theory (DFT) calculations of the electronic density of states identified Ni1.0Co₂O₄ with optimal band-gap of 2.38 eV with an expectation of displaying higher electrocapacitive performance. Experimentally, Ni0.92Co2.08O₄ displayed superior electrocapacitive performance among all Ni/Co ratio in NixCo3-xO₄. The DFT study also predicted Ni preference to the octahedral site, which is in-line with the observed increase in ferromagnetic nature, decreased lattice parameter, and increased structural disorder with increasing Ni/Co ratio. The improved electrochemical performance of NixCo3-xO₄ (x > 0) is attributed to the mesoporous hierarchical structure, with a high electroactive surface which can effectively improve structural stability, and reduce the ionic and electron diffusion length. Compared to the pure Co₃O₄, the reduction of Co content in NixCo3-xO₄ is desired due to the high cost and toxicity of Co element.
Collapse
Affiliation(s)
- M Ghimire
- Department of Physics and Materials Science, The University of Memphis, Memphis, TN 38152, USA
| | - S Bhoyate
- Department of Chemistry, Pittsburg State University, Pittsburg, KS 66762, USA
| | - R K Gupta
- Department of Chemistry, Pittsburg State University, Pittsburg, KS 66762, USA
| | - X Shen
- Department of Physics and Materials Science, The University of Memphis, Memphis, TN 38152, USA
| | - F Perez
- Integrated Microscopy Center, IMC, The University of Memphis, Memphis, TN 38152, USA
| | - J Alam
- Department of Physics and Materials Science, The University of Memphis, Memphis, TN 38152, USA
| | - S R Mishra
- Department of Physics and Materials Science, The University of Memphis, Memphis, TN 38152, USA
| |
Collapse
|
10
|
Abstract
The present study was carried out to determine the morphological structure and the branches of the lumbosacral plexus in the indigenous duck (Anas platyrhynchos domesticus). Six mature indigenous ducks were used in this study. After administering an anesthetic to the birds, the body cavities were opened. The nerves of the lumbosacral plexus were dissected separately and photographed. The lumbosacral
plexus consisted of lumbar and sacral plexus innervated to the hind limb. The lumbar plexus was formed by the union of three roots of spinal nerves that included last two and first sacral spinal nerve. Among three roots, second (middle) root was the highest in diameter and the last root was least in diameter. We noticed five branches of the lumbar plexus which included obturator, cutaneous femoral, saphenus, cranial coxal, and the femoral nerve. The six roots of spinal nerves, which contributed to form three
trunks, formed the sacral plexus of duck. The three trunks united medial to the acetabular foramen and formed a compact, cylindrical bundle, the ischiatic nerve. The principal branches of the sacral plexus were the tibial and fibular nerves that together made up the ischiatic nerve. Other branches were the caudal coxal nerve, the caudal femoral cutaneous nerve and the muscular branches. This study was the first work on the lumbosacral plexus of duck and its results may serve as a basis for further investigation on this subject.
Collapse
|
11
|
Zeltz C, Alam J, Liu H, Erusappan PM, Hoschuetzky H, Molven A, Parajuli H, Cukierman E, Costea DE, Lu N, Gullberg D. α11β1 Integrin is Induced in a Subset of Cancer-Associated Fibroblasts in Desmoplastic Tumor Stroma and Mediates In Vitro Cell Migration. Cancers (Basel) 2019; 11:E765. [PMID: 31159419 PMCID: PMC6627481 DOI: 10.3390/cancers11060765] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2019] [Revised: 05/26/2019] [Accepted: 05/29/2019] [Indexed: 01/06/2023] Open
Abstract
Integrin α11β1 is a collagen receptor that has been reported to be overexpressed in the stroma of non-small cell lung cancer (NSCLC) and of head and neck squamous cell carcinoma (HNSCC). In the current study, we further analyzed integrin α11 expression in 14 tumor types by screening a tumor tissue array while using mAb 203E3, a newly developed monoclonal antibody to human α11. Different degrees of expression of integrin α11 were observed in the stroma of breast, ovary, skin, lung, uterus, stomach, and pancreatic ductal adenocarcinoma (PDAC) tumors. Co-expression queries with the myofibroblastic cancer-associated fibroblast (myCAF) marker, alpha smooth muscle actin (αSMA), demonstrated a moderate level of α11+ in myCAFs associated with PDAC and HNSCC tumors, and a lack of α11 expression in additional stromal cells (i.e., cells positive for fibroblast-specific protein 1 (FSP1) and NG2). The new function-blocking α11 antibody, mAb 203E1, inhibited cell adhesion to collagen I, partially hindered fibroblast-mediated collagen remodeling and obstructed the three-dimensional (3D) migration rates of PDAC myCAFs. Our data demonstrate that integrin α11 is expressed in a subset of non-pericyte-derived CAFs in a range of cancers and suggest that α11β1 constitutes an important receptor for collagen remodeling and CAF migration in the tumor microenvironment (TME).
Collapse
Affiliation(s)
- Cédric Zeltz
- Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, NO-5009 Bergen, Norway.
| | - Jahedul Alam
- Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, NO-5009 Bergen, Norway.
| | - Hengshuo Liu
- Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, NO-5009 Bergen, Norway.
| | - Pugazendhi M Erusappan
- Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, NO-5009 Bergen, Norway.
| | - Heinz Hoschuetzky
- nanoTools Antikörpertechnik, Tscheulinstr. 21, 79331 Teningen, Germany.
| | - Anders Molven
- Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, NO-5020 Bergen, Norway.
- Department of Pathology, Haukeland University Hospital, NO-5020 Bergen, Norway.
| | - Himalaya Parajuli
- Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, NO-5009 Bergen, Norway.
| | - Edna Cukierman
- Cancer Biology Department, Fox Chase Cancer Center, Temple Health, Philadelphia, PA 19111, USA.
| | - Daniela-Elena Costea
- Department of Pathology, Haukeland University Hospital, NO-5020 Bergen, Norway.
- Department of Clinical Medicine, Center for Cancer Biomarkers CCBIO and Gade Laboratory for Pathology, University of Bergen, NO-5020 Bergen, Norway.
| | - Ning Lu
- Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, NO-5009 Bergen, Norway.
| | - Donald Gullberg
- Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Jonas Lies vei 91, NO-5009 Bergen, Norway.
| |
Collapse
|
12
|
Beck JT, Neven P, Esteva FJ, Bardia A, Harbeck N, Hurvitz S, O'Shaughnessy J, Verma S, Lanoue B, Alam J, Kong O, Chandiwana D, Chia S. Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-14] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In the Phase III MONALEESA (ML) trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + endocrine therapy (ET) significantly improved progression-free survival (PFS) vs placebo (PBO) + ET in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). Here we report key patient-reported outcomes (PROs) for pts treated with RIB-based regimens of interest (i.e. with a non-steroidal aromatase inhibitor [NSAI] or fulvestrant [FUL]) in the ML-2, -3, and -7 trials.
Methods: Postmenopausal pts with HR+, HER2– ABC and no prior ET for advanced disease received RIB (600 mg/day; 3-weeks-on/1-week-off) + letrozole (2.5 mg/day; ML-2 [NCT01958021]), or FUL (500 mg every 28 days, with an additional dose on Day 15 of Cycle [C] 1; ML-3 [no prior ET for ABC subgroup only; NCT02422615]). Premenopausal pts with no prior ET and ≤1 line of chemotherapy for advanced disease received RIB + NSAI (anastrozole [1 mg/day]/letrozole [2.5 mg/day]) + goserelin (3.6 mg every 28 days; ML-7 [NCT02278120]). The primary endpoint for all trials was PFS. PROs were a secondary endpoint of all trials and were evaluated using EORTC QLQ-C30, QLQ-BR23 (ML-2 and ML-7), EQ-5D-5L, WPAI-GH (ML-7 only), and BPI-SF (ML-3 only) questionnaires. Changes from baseline and time to 10% deterioration (TTD) in health-related quality of life (HRQoL) were analyzed using linear mixed-effect and stratified Cox regression models, respectively.
Results: A total of 1530 pts were included in this analysis. Questionnaire compliance was high across trials (ML-2/ML-3: >90%; ML-7: >80%). On-treatment HRQoL (EORTC QLQ-C30 global health status/quality of life [QoL] score) was maintained from baseline up to C34, C28, and C17 in both treatment arms for ML-2, ML-3, and ML-7, respectively. In ML-7, mean overall HRQoL scores continued to improve in the RIB arm from C18 to C28, but scores decreased in the PBO arm. At end of treatment, mean overall HRQoL scores decreased in both arms across trials. Median TTD (RIB vs PBO) was similar between arms, favoring the RIB arms (ML-2: 27.7 vs 27.6 months; hazard ratio 0.944; 95% confidence interval [CI] 0.720–1.237; ML-3: not reached [NR] vs 22.4 months; hazard ratio 0.721; 95% CI 0.484–1.074; ML-7: 24.0 vs 19.4 months; hazard ratio 0.759; 95% CI 0.561–1.028). Clinically meaningful reductions in EORTC QLQ-C30 pain score (>5 points from baseline) were observed in the RIB arm of ML-2 from as early as C3 and were sustained vs only at C7 and C13 in the PBO arm. Clinically meaningful reductions in pain were observed from C22 to C28 in the RIB arm of ML-7 vs only at C28 in the PBO arm. In ML-3, clinically meaningful reductions in pain were observed from C3 to C5, C11–17, and at C22 and C28 in the RIB arm vs C17–C25 in the PBO arm. Furthermore, median TTD of the BPI-SF pain severity index score was NR in either arm of ML-3 (hazard ratio 0.858; 95% CI 0.554–1.330).
Conclusions: In addition to significantly prolonging PFS, RIB consistently maintains QoL regardless of ET combination partner. RIB + ET is also associated with clinically meaningful reductions in pain vs PBO + ET across a broad population of pts with HR+, HER2– ABC.
Citation Format: Beck JT, Neven P, Esteva FJ, Bardia A, Harbeck N, Hurvitz S, O'Shaughnessy J, Verma S, Lanoue B, Alam J, Kong O, Chandiwana D, Chia S. Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-14.
Collapse
Affiliation(s)
- JT Beck
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| | - P Neven
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| | - FJ Esteva
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| | - A Bardia
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| | - N Harbeck
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| | - S Hurvitz
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| | - J O'Shaughnessy
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| | - S Verma
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| | - B Lanoue
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| | - J Alam
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| | - O Kong
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| | - D Chandiwana
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| | - S Chia
- Highlands Oncology Group, Fayetteville; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; NYU Langone Health, New York; Massachusetts General Hospital, Harvard Medical School, Boston; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, Dallas; Tom Baker Cancer Centre, Calgary, Canada; Novartis Pharmaceuticals Corporation, East Hanover; BC Cancer Agency, Vancouver, Canada
| |
Collapse
|
13
|
Beck JT, Neven P, Sohn J, Chan A, Sonke GS, Bachelot T, Campos-Gomez S, Martin M, Bardia A, Alam J, Miller M, Diaz-Padilla I, Kong O, Hart L. Abstract P6-18-06: Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-06] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In the MONALEESA (ML) trials, addition of ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) to endocrine therapy (ET) prolonged progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). RIB was generally well tolerated, with adverse events (AEs) managed effectively by dose modifications. Here we present efficacy data for RIB-based regimens of interest for the proposed indication (i.e. with a non-steroidal aromatase inhibitor [NSAI] or fulvestrant [FUL]) from ML-2, -3, and -7 in pts who received no prior ET for ABC and who had ≥1 RIB dose reduction, to explore the efficacy of RIB in pts who need to dose reduce.
Methods: Pts included in this analysis were: postmenopausal women with HR+, HER2– ABC and no prior ET for ABC who received RIB (600 mg; 3-weeks-on/1-week-off) with letrozole (2.5 mg/day; ML-2 [NCT01958021]), or FUL (500 mg per label; ML-3 [NCT02422615]); and premenopausal women with no prior ET and ≤1 line of chemotherapy for ABC who received RIB with an NSAI (anastrozole: 1 mg/day; letrozole: 2.5 mg/day; ML-7 [NCT02278120]) plus goserelin (3.6 mg every 28 days). Dose reductions for RIB (600 to 400 to 200 mg) were permitted. Primary endpoint was PFS. Secondary endpoints included overall response rate (ORR), clinical benefit rate (CBR), and safety.
Results: In ML-2, -3, and -7, ≥1 RIB dose reduction occurred (n/N) in 169/334 (51%), 92/238 (39%), and 91/246 (37%) pts assigned to RIB, respectively. AEs were the main reason for dose reduction, with all-grade neutropenia the most common AE leading to dose reduction (ML-2 69%, ML-3 80%, ML-7 82%). Median PFS (months) was prolonged with RIB vs placebo in pts without a RIB dose reduction (ML-2: 27.7 vs 16.0; ML-3: not reached [NR] vs 18.3; ML-7: 23.8 vs 13.8); median PFS in pts with ≥1 RIB dose reduction was: ML-2 25.3, ML-3 NR, and ML-7 27.5 months. In pts with measurable disease and without a RIB dose reduction, ORR was 46% (ML-2), 43% (ML-3), and 48% (ML-7); CBR was 70%, 68%, and 79%, respectively. In pts with measurable disease and ≥1 RIB dose reduction, ORR was 62% (ML-2), 57% (ML-3), and 55% (ML-7); CBR was 88%, 85%, and 88%, respectively. The most common Grade 3/4 AEs in the RIB vs placebo groups (≥5% of pts in either ML trial, irrespective of causality or dose reduction) were neutropenia (ML-2: 62% vs 1%; ML-3: 55% vs 0; ML-7: 65% vs 4%), leukopenia (ML-2: 21% vs 1%; ML-3: 12% vs 0; ML-7: 16% vs 1%), hypertension (ML-2: 13% vs 13%; ML-3: 5% vs 5%; ML-7: 2% vs 3%), increased alanine aminotransferase (ML-2: 10% vs 1%; ML-3: 10% vs 0; ML-7: 5% vs 1%), and increased aspartate aminotransferase (ML-2: 6% vs 1%; ML-3: 6% vs 0; ML-7: 4% vs 1%).
Conclusions: Results from the ML-2, -3, and -7 trials suggest that pts who start on 600 mg of RIB and require dose reduction for the management of their AEs, or for other reasons, continue to derive clinical benefit.
Citation Format: Beck JT, Neven P, Sohn J, Chan A, Sonke GS, Bachelot T, Campos-Gomez S, Martin M, Bardia A, Alam J, Miller M, Diaz-Padilla I, Kong O, Hart L. Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-06.
Collapse
Affiliation(s)
- JT Beck
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - P Neven
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - J Sohn
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - A Chan
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - GS Sonke
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - T Bachelot
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - S Campos-Gomez
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - M Martin
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - A Bardia
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - J Alam
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - M Miller
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - I Diaz-Padilla
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - O Kong
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| | - L Hart
- Highlands Oncology Group, Fayetteville, AR; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; Severance Hospital, Yonsei University Health System, Seoul, Korea; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Netherlands Cancer Institute/BOOG Study Center, Amsterdam, Netherlands; Centre Léon Bérard, Lyon, France; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto de Investigación Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense de Madrid, Madrid, Spain; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL
| |
Collapse
|
14
|
Im SA, Sohn J, Tripathy D, Chow L, Lee K, Jung K, Babu G, Im YH, El Saghir N, Liu MC, Diaz-Padilla I, Alam J, Kong O, Miller M, Lu YS. Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy428] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Alam J, Blackburn K, Patrick D. Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease. J Prev Alzheimers Dis 2018; 4:273-278. [PMID: 29181493 DOI: 10.14283/jpad.2017.41] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Neflamapimod (previously code named VX-745) is a clinical phase 2b-ready highly specific inhibitor of the intra-cellular enzyme p38 mitogen activated protein kinase alpha ("p38α") that is being developed as a disease-modifying drug for Alzheimer's disease (AD) that acts via targeting synaptic dysfunction. Neflamapimod was discovered through a proprietary structure-based drug discovery platform at Vertex Pharmaceuticals, and developed previously by Vertex through to phase 2a in rheumatoid arthritis. EIP Pharma licensed the compound in 2014 for development and commercialization as a treatment of central nervous system (CNS) disorders. Neflamapimod is the most advanced in the clinic drug that targets specific molecular mechanisms within neurons that leads to synaptic dysfunction, the pathogenic process that is now considered to be a major driver of the development of memory deficits and disease progression in the early stages of AD. Based on the scientific rationale of targeting synaptic dysfunction and the preclinical data, neflamapimod has the potential to both reverse memory deficits and slow disease progression. Phase 2a clinical data in patients with early-stage AD (MMSE 20-28, biomarker positive) provides evidence that the preclinical science may be translatable to human Alzheimer's, as 6- to 12-weeks of neflamapimod treatment led to significant improvement in episodic memory, the best clinical measure of synaptic dysfunction in AD. A phase 2b six-month placebo-controlled 150-patient clinical study is anticipated to start by end of 2017. This study is designed to definitively demonstrate that neflamapimod reverses memory deficits, and also to provide preliminary evidence that the drug slows disease progression.
Collapse
Affiliation(s)
- J Alam
- John Alam, MD, EIP Pharma, LLC, 11 Channing Street, Cambridge MA 02138, phone: 617-945-0794,
| | | | | |
Collapse
|
16
|
Jerusalem G, Fasching P, Martín M, Pivot X, Petrakova K, Bianchi G, Nusch A, Sonke G, De La Cruz Merino L, Vagnon E, Alam J, Kong O, Chandiwana D, De Laurentiis M. Ribociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Harbeck N, Villanueva R, Franke F, Babu G, Wheatley-Price P, Im YH, Altundag K, Lanoue B, Alam J, Chandiwana D, Colleoni M. Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.283] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Bardia A, Campos-Gomez S, Hurvitz S, Lu YS, Im SA, Franke F, Chow L, Wheatley-Price P, Melo Cruz F, Alam J, Kong O, Diaz-Padilla I, Miller M, Tripathy D. Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.320] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Khan KA, Alam J, Nahar N, Dey SK, Mannan MA, Shahidullah M. Predicting Neonatal Hyperbilirubinemia Using First Day Serum Bilirubin Level in Late Preterm and Term Healthy Newborn. Mymensingh Med J 2017; 26:854-862. [PMID: 29208875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Hyperbilirubinemia is a common problem during the neonatal period and is the most common reason for readmission after early hospital discharge of the healthy near term and term infants. This early discharge policy along with limited follow-up facilities in developing countries and inadequate communication between physicians and parents necessitates a prognostic test to predict hyperbilirubinemia in these newborns; for early and effective management and prevention of potential complication before it occurred. This observational analytical study was done to determine the predictability of day1 total serum bilirubin (TSB) level as a screening test and identify the best cutoff value which would predict neonates likely to develop significant hyperbilirubinemia. The study was carried out in the Department of Neonatology and Department of Gynecology and Obstetrics, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from 1st April 2013 to 31st March 2014. A TSB level of ≥17mg/dl after 72 hours was defined as significant hyperbilirubinemia. By purposive sampling method, 100 healthy late preterm and term neonates fulfilling the inclusion criteria were enrolled and 89 were finally analyzed. Among 89 neonates 14(15.74%) developed significant hyperbilirubinemia (Group II) and 75(84.26%) did not develop hyperbilirubinemia (Group I). Mean time of sample collection was similar in both groups. Mean TSB level on day1 was significantly higher in Group II (5.97±1.74mg/dl) than Group I (3.19±1.4mg/dl). By using ROC (Receiver Operating Characteristic) analysis, TSB level of 5.65mg/dl on day 1 has the best combination of sensitivity (86%) and specificity (91%) to predict neonates at risk of significant hyperbilirubinemia (AUC-0.880, p=0.001). At this cut-off PPV was 63% and NPV 97%. Total serum bilirubin level on first day of life predicts neonates at risk of subsequent significant hyperbilirubinemia and late preterm and term babies with TSB level of ≥5.65mg/dl on day 1 of life should be followed up strictly either in the hospital or in the outpatient department on day 5.
Collapse
Affiliation(s)
- K A Khan
- Dr Md Kamrul Ahsan Khan, Assistant Professor (Neonatology), Department of Pediatrics, Sheikh Sayera Khatun Medical College, Gopalgonj, Bangladesh
| | | | | | | | | | | |
Collapse
|
20
|
Abstract
We recently reported the presence of anti-aquaporin 5 (AQP5) immunoglobulin G (IgG) in patients with primary Sjögren syndrome (SS) with a sensitivity of 0.73 and a specificity of 0.68. The aim of this study was to identify functional epitopes for the anti-AQP5 autoantibodies detected in control subjects and patients with SS. Recognition of epitopes by anti-AQP5 autoantibodies in sera ( n = 13 for control and n = 24 for SS) or purified IgG ( n = 1 for control and n = 3 for SS) was evaluated by indirect immunofluorescence (IIF) assay performed in the presence or absence of peptides corresponding to the second transmembrane helix and extracellular loops A, C, and E of AQP5. Functional epitopes were determined by measuring the effects of purified IgG and neutralizing peptides on transepithelial osmotic permeability (PfT) of MDCK cells expressing AQP5. In the IIF assay, 89% of SS samples were inhibited by at least 1 peptide, while only half of control samples were inhibited by any peptide. Overall, SS samples were inhibited by peptides corresponding to extracellular loops A, C, and E by 40% to 50%, whereas control samples were inhibited only by peptides corresponding to loop E by <20%. A cyclized peptide (E1) mimicking loop E was most frequently recognized and best differentiated between the SS and control samples. Incubation of MDCK-AQP5 cells with SS but not with control IgG, significantly decreased PfT, which was reversed by neutralization of IgG binding to any of the extracellular loops. In conclusion, the anti-AQP5 autoantibodies detected in control and SS groups showed differences in fine specificity to the functional epitopes of AQP5. The prevalent recognition of functional epitopes by anti-AQP5 autoantibodies from SS patients suggests that anti-AQP5 autoantibodies act as mediators of glandular hypofunction and are a potential therapeutic target in SS.
Collapse
Affiliation(s)
- J Alam
- 1 School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea
| | - J H Koh
- 2 Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
| | - S-K Kwok
- 2 Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
| | - S-H Park
- 2 Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
| | - K Park
- 1 School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea
| | - Y Choi
- 1 School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea
| |
Collapse
|
21
|
Iba MM, Alam J. Heme oxygenase-1 mRNA levels, metallothionein mRNA levels, lipid peroxidation and microsomal CYP1A activities in rats treated with 3,3-dichlorobenzidine and some other inducers of P450. Redox Rep 2016; 1:279-86. [DOI: 10.1080/13510002.1995.11746998] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
22
|
Beall DP, Feldman RG, Gordon ML, Gruber BL, Lane JM, Valenzuela G, Yim D, Alam J, Krege JH, Krohn K. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study. Osteoporos Int 2016; 27:1191-1198. [PMID: 26556737 DOI: 10.1007/s00198-015-3353-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2014] [Accepted: 09/29/2015] [Indexed: 12/31/2022]
Abstract
SUMMARY In patients in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study with and without a prior vertebral or hip fracture, the incidence of nonvertebral fractures was lower with >6 months of teriparatide treatment than during the first 6 months. INTRODUCTION Clinical evidence on the effect of teriparatide in patients with prior fracture is limited. In the DANCE observational study, the incidence of nonvertebral fragility fractures (NVFX) decreased significantly in patients receiving teriparatide for >6 months (6-24 months) versus >0 to ≤6 months (reference period). METHODS We performed a post hoc analysis to assess the effect of teriparatide 20 μg/day in patients who entered DANCE with prior vertebral or hip fractures. The incidence of patients experiencing a NVFX for four 6-month intervals during and after treatment was compared with the reference period. RESULTS Overall, 4085 patients received ≥1 dose of teriparatide. Of 3720 with sufficient data for efficacy analysis, 692 had prior vertebral fracture, including 179 with previous kyphoplasty/vertebroplasty; 290 had prior hip fracture. These patients were older, and those with prior vertebral fractures had more comorbid conditions at baseline than those without prior vertebral fractures. The incidence of patients experiencing NVFX declined over time in all patient groups. The fracture incidence rate declined 49 and 46%, respectively, in patients with and without prior vertebral fracture and was 63 and 46% lower in patients with previous kyphoplasty/vertebroplasty and without prior vertebral fracture. NVFX declined 43 and 48% in patients with and without prior hip fracture. The reduced incidence over time was consistent in the subgroups (all interaction p values >0.05). Patients with prior fracture were more likely to experience serious adverse events. CONCLUSION The incidence of NVFX decreased over time in patients receiving teriparatide in DANCE regardless of prior fracture status.
Collapse
Affiliation(s)
- D P Beall
- Clinical Radiology of Oklahoma, 1800 S. Renaissance Blvd, Edmond, OK, 73013, USA
| | - R G Feldman
- Senior Clinical Trials, Inc., 23961 Calle de la Magdalena Suite 429, Laguna Hills, CA, 92653, USA
| | - M L Gordon
- Newport Orthopedic Institute, Newport Beach 22 Corporate Plaza Drive, Newport Beach, CA, 92660, USA
| | - B L Gruber
- Long Island Regional Arthritis and Osteoporosis Care, PC, 500 West Main Street, Suite 110, Babylon, NY, 11702, USA
| | - J M Lane
- Hospital for Special Surgery, Weill Cornell Medical College, Ground Floor 523 East 72nd Street, New York, NY, 10021, USA
| | - G Valenzuela
- Integral Rheumatology & Immunology Specialists, 140 SW 84th Avenue, Fort Lauderdale, FL, 33324, USA
| | - D Yim
- UC Irvine Medical Center, 101 The City Drive South, Route 140, Orange, CA, 92868, USA
| | - J Alam
- Lilly USA, LLC, Indianapolis, IN, 46285, USA
| | - J H Krege
- Lilly USA, LLC, Indianapolis, IN, 46285, USA
| | - K Krohn
- Lilly USA, LLC, Indianapolis, IN, 46285, USA.
| |
Collapse
|
23
|
Ellinger J, Alam J, Rothenburg J, Deng M, Schmidt D, Syring I, Miersch H, Perner S, Müller SC. The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. Am J Cancer Res 2015; 5:2799-2807. [PMID: 26609485 PMCID: PMC4633906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Accepted: 08/05/2015] [Indexed: 06/05/2023] Open
Abstract
Clear cell renal cell carcinoma (ccRCC) is among the most common human malignancies. Long non-coding RNAs (lncRNA) regulate various cellular functions and have been implicated in ccRCC pathogenesis. In order to decipher the molecular biology of this tumor and to identify potential prognostic biomarkers and therapeutic targets, we re-evaluated published lncRNA expression profiling data. An expression profile of 49 lncRNAs allowed discrimination of localized and advanced ccRCC. The expression profile of six lncRNAs transcripts (lnc-ACO1625, lnc-CYP4A22-2/3, lnc-PEAK1.1-1, lnc-PCYOX1L, lnc-VCAN-1, lnc-ZNF180-2) with potential prognostic interest were validated in a cohort of 50 normal renal, 57 localized ccRCC and 45 advanced ccRCC tissues. lnc-ZNF180-2 levels were similar in localized ccRCC and normal renal tissue, but we observed a significant increase of lnc-ZNF180-2 expression in advanced ccRCC tissue. Furthermore, lnc-ZNF180-2 expression levels were an independent predictor of progression-free survival, cancer-specific survival and overall survival in ccRCC patients. We also observed that lnc-CYP4A22-2/3 expression levels allowed discrimination of ccRCC and normal renal tissue. In conclusion, lncRNAs are involved in renal carcinogenesis, and quantification of lnc-ZNF180-2 may be useful for the prediction of ccRCC patients outcome following nephrectomy.
Collapse
Affiliation(s)
- Jörg Ellinger
- Department of Urology, University Hospital BonnBonn, Germany
| | - Jahedul Alam
- Department of Urology, University Hospital BonnBonn, Germany
| | | | - Mario Deng
- Section for Prostate Cancer Research, Institute of Pathology, University Hospital BonnBonn, Germany
| | - Doris Schmidt
- Department of Urology, University Hospital BonnBonn, Germany
| | - Isabella Syring
- Department of Urology, University Hospital BonnBonn, Germany
| | - Herdis Miersch
- Department of Urology, University Hospital BonnBonn, Germany
| | - Sven Perner
- Section for Prostate Cancer Research, Institute of Pathology, University Hospital BonnBonn, Germany
| | - Stefan C Müller
- Department of Urology, University Hospital BonnBonn, Germany
| |
Collapse
|
24
|
Rahman T, Khalequezzaman S, Ahsan S, Alam J, Sarker MK. A case report of congenital high airway obstruction syndrome (CHAOS) caused by complete laryngeal obstruction. Pulse (Basel) 2015. [DOI: 10.3329/pulse.v7i1.23248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
CHAOS or Congenital High Airway Obstruction Syndrome is a blockage of the fetuss trachea or larynx due to a number of factors including narrowing of the airway, a web-like membrane or even tracheal atresia. In the uterus, the fetal lungs constantly produce fluid and as a result of this airway blockage in the trachea, the lung fluid cannot escape out of the fetal mouth. Because of this the fetuss lungs become distended with fluid and over distended lungs can put pressure on the heart and affect the hearts ability to function. If the heart cannot beat effectively hydrops or congestive heart failure can occur. We present a case of CHAOS with hydrops and associated anomalies, determined prenatally at about 21 weeks by MRI in our hospital.Pulse Vol.7 January-December 2014 p.38-41
Collapse
|
25
|
Ruby FA, Ahsan S, Chandy MJ, Alam J. A case of mr imaging detection of hemorrhages in cerebral amyloid angiopathy. Pulse (Basel) 2015. [DOI: 10.3329/pulse.v7i1.23252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
A 70-year-old diabetic and hypertensive male patient with mild renal impairment presented with recurrent stroke. CT scan of brain demonstrated acute hemorrhagic / nonhemorrhagic infarcts in the brain. Gradient sequences in the follow-up MRI showed extensive blooming in the cortex of both cerebral hemispheres. There were multiple foci of blooming in basal ganglia and cerebellar hemispheres. Hemosiderin staining was present in posterior fossa. MR findings were consistent with extensive primary cerebral amyloid angiopathy (CAA).Pulse Vol.7 January-December 2014 p.53-55
Collapse
|
26
|
Awal M, Alam J, Hossain M, Matsumoto M. Effect of Arsenic (As) on the Spermatogenesis of Black Bengal Goat (Capra hircus) Reared at the Arsenic Prone Area of Mymensingh District in Bangladesh. ACTA ACUST UNITED AC 2015. [DOI: 10.9734/bbj/2015/12325] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
27
|
Khan BS, Alam J. Progressive Multifocal Leukoencephalopathy (PML) a Case Report. Pulse (Basel) 2014. [DOI: 10.3329/pulse.v6i1-2.20355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Progressive Multifocal Leukoencephalopathy (PML) is a rare and usually fatal viral disease occurring almost exclusively in people with severe immune deficiency. This is a demyelinating disease of the central nervous system (CNS) that usually leads to death or severe disability. Patients usually present with focal CNS abnormalities like; hemiparesis, apathy, and confusion. Multifocal white matter lesions without mass effect lead to the diagnosis of PML. In this article we present a review of literature and report of a case of PML in which the patients clinical status and MR findings are typical. DOI: http://dx.doi.org/10.3329/pulse.v6i1-2.20355 Pulse Vol.6 January-December 2013 p.57-59
Collapse
|
28
|
Parvin A, Khan BS, Alam J, Ruby FA, Iqbal TJ. Uterine Didelphys Associated With Obstructed Hemivagina and Ipsilateral Renal Anomaly (OHVIRA) Syndrome: a Case Report. Pulse (Basel) 2014. [DOI: 10.3329/pulse.v6i1-2.20358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
A 30 year old nulligravida female reported to the fertility centre of AHD with the complaints of primary infertility for three and half years and spasmodic dysmenorrhoea. There is also history of progressively increasing right lower abdominal pain as well as discomfort which was cyclically associated with the onset of menses. Transabdominal sonography showed-Endometrial splitting into two at the fundussuggesting bicornuate uterus. Echogenic soft tissue in the cervical canal due to blood clots. Non visualized right kidney. Mildly enlarged left kidney. HSG done outside AHD suggestive of unicornuate uterus with single fallopian tube. IVU showed non visualized right kidney. Normally excreting left kidney. TVS showed normal sized septated nulliparus uterus with homogeneous myometrium and thick endometrium with proliferative phase echo. Mildly enlarged right ovary with mildly distended right tube. Mild collection adjacent to the vagina. Then the patient came to the gynaecology dept of AHD from where she was sent to our Radiology department to undergo MRI of pelvis. The MRI showed uterine didelphys. Obstructed hemivagina (right) with hematocolpos extended upto pelvic brim along right and posterior aspect of uterus through anomalous dilated remnant of right lower ureter with ipsilateral renal agenesis. Patient was diagnosed as OHVIRA syndrome radiologically. DOI: http://dx.doi.org/10.3329/pulse.v6i1-2.20358 Pulse Vol.6 January-December 2013 p.66-69
Collapse
|
29
|
Krohn K, Valenzuela G, Lane J, Gruber B, Alam J, Chiang A, Krege J. Effect of Prior Hip Fracture Status in Patients With Osteoporosis Receiving Teriparatide. J Clin Densitom 2014. [DOI: 10.1016/j.jocd.2014.04.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
30
|
Abstract
The experiment was carried out to determine the gross and microscopic effects of arsenic on uterus of female Black Bengal Goats against control group in the Department of Anatomy and Histology, Faculty of Veterinary Science, Bangladesh Agricultural University, Mymensingh-2202. A total of twelve mature female Black Bengal goats were studied, six from arsenic affected areas of Mymensingh district and theother six from Hill Tracts of Bangaldesh which are arsenic free. Gross parameters show slight variations in the morphology (color and shape) and biometry (size and weight) of uterus of arsenic affected Black Bengal goats, but this variation was statistically insignificant (p>0.05). For microscopic study, permanent slide was prepared by Mayers Hematoxylin and Eosin stain method. In microscopic level, there were significant variations in arsenic affected group of goats compared to the control group. Arsenic affected group of goats show thickening of uterine horn (p<0.01), uterine gland is lower in amount and diameter(p<0.01), cervical villi length was smaller (p<0.01), cervical wall thickness was higher (p<0.01). This work may be the tip of the iceberg representing the full extent of arsenic exposure to female genital tract. DOI: http://dx.doi.org/10.3329/bjvm.v11i1.13175 Bangl. J. Vet. Med. (2013). 11 (1): 61-68
Collapse
|
31
|
Silverman S, Miller P, Sebba A, Weitz M, Wan X, Alam J, Masica D, Taylor KA, Ruff VA, Krohn K. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporos Int 2013; 24:2309-17. [PMID: 23404615 PMCID: PMC3706736 DOI: 10.1007/s00198-013-2284-y] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2012] [Accepted: 01/03/2013] [Indexed: 11/04/2022]
Abstract
UNLABELLED This observational study evaluated the occurrence of nonvertebral fragility fractures (NVFX) in over 4,000 men and women with osteoporosis treated with teriparatide (TPTD). The incidence of new NVFX decreased for patients receiving TPTD treatment for greater than 6 months. No new significant safety findings were observed in this large trial. INTRODUCTION The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study evaluated the occurrence of NVFX in patients receiving TPTD for osteoporosis in a real-world setting. METHODS DANCE is a multicenter, prospective, observational trial that examined the long-term effectiveness of TPTD in men and women with osteoporosis whom study physicians judged to be suitable for TPTD therapy. Patients received 20 μg TPTD per day by subcutaneous injection for up to 24 months and were followed for 24 months after treatment cessation. The incidence of patients experiencing a new NVFX, defined as a fracture associated with low trauma, was evaluated during four 6-month periods in both the treatment and cessation phases with >0 to ≤6 months serving as the reference. We also observed the spectrum and occurrence of serious adverse events. RESULTS Of the 4,167 patients enrolled, 4,085 took one or more doses of TPTD (safety population); 3,720 were included in the efficacy analysis. The incidence of patients experiencing a NVFX was 1.42, 0.91, 0.70, and 0.81 % for the four treatment periods, respectively, and 0.80, 0.68, 0.33, and 0.33 % for the four periods after treatment cessation. Differences for each period were statistically significant compared with the reference period (first 6-month interval, each p < 0.05). No new significant safety findings were observed. CONCLUSIONS In this study, the incidence of NVFX decreased for patients receiving TPTD for all three treatment periods >6 months compared to 0 to ≤6 months, and this trend persisted throughout the cessation phase. TPTD was generally well tolerated.
Collapse
Affiliation(s)
- S Silverman
- Cedars-Sinai/UCLA Medical Center and OMC Clinical Research Center, 8641 Wilshire Blvd, Suite 301, Beverly Hills, CA 90211, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 2012; 23:2141-50. [PMID: 22159672 DOI: 10.1007/s00198-011-1856-y] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2011] [Accepted: 11/04/2011] [Indexed: 10/14/2022]
Abstract
UNLABELLED The effect of teriparatide and risedronate on back pain was tested, and there was no difference in the proportion of patients experiencing a reduction in back pain between groups after 6 or 18 months. Patients receiving teriparatide had greater increases in bone mineral density and had fewer vertebral fractures. INTRODUCTION This study aimed to understand the effect of teriparatide in reducing back pain in patients with prevalent back pain and vertebral fracture compared to risedronate. METHODS In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture. The primary objective was to compare the proportion of subjects reporting ≥30% reduction in worst back pain severity from baseline to 6 months as assessed by a numeric rating scale in each treatment group. Pre-specified secondary and exploratory outcomes included assessments of average and worst back pain at additional time points, disability and quality of life, bone mineral density, incidence of fractures, and safety. RESULTS At 6 months, 59% of teriparatide and 57% of risedronate patients reported ≥30% reduction in worst back pain and there were no differences between groups in the proportion of patients experiencing reduction in worst or average back pain at any time point, disability, or quality of life. There was a greater increase from baseline in bone mineral density at the lumbar spine (p = 0.001) and femoral neck (p = 0.02) with teriparatide compared to risedronate and a lower incidence of vertebral fractures at 18 months (4% teriparatide and 9% risedronate; p = 0.01). Vertebral fractures were less severe (p = 0.04) in the teriparatide group. There was no difference in the overall incidence of adverse events. CONCLUSIONS Although there were no differences in back pain-related endpoints, patients receiving teriparatide had greater skeletal benefit than those receiving risedronate.
Collapse
Affiliation(s)
- P Hadji
- Department of Endocrinology, Osteoporosis, and Reproductive Medicine, Philipps-University of Marburg, Marburg, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Gleeson L, Alam J, Lane S. SMART phones and the acute respiratory patient. Ir Med J 2012; 105:143-146. [PMID: 22803492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Definition of Respiratory Failure using PaO2 alone is confounded when patients are commenced on oxygen therapy prior to arterial blood gas (ABG) measurement. Furthermore, classification of Respiratory Failure as Type 1 or Type 2 using PaCO2 alone can give an inaccurate account of events as both types can co-exist. 100 consecutive presentations of acute respiratory distress were assessed initially using PaO2, and subsequently PaO2/FiO2 ratio, to diagnose Respiratory Failure. Respiratory Failure cases were classified as Type 1 or Type 2 initially using PaCO2, and subsequently alveolar-arterial (A-a) gradient. Any resultant change in management was documented. Of 100 presentations, an additional 16 cases were diagnosed as Respiratory Failure using PaO2/FiO2 ratio in place of PaO2 alone (p = 0.0338). Of 57 cases of Respiratory Failure, 22 cases classified as Type 2 using PaCO2 alone were reclassified as Type 1 using A-a gradient (p < 0.001). Of these 22 cases, management changed in 18.
Collapse
Affiliation(s)
- L Gleeson
- Department of Respiratory Medicine, AMNCH, Tallaght, Dublin 24.
| | | | | |
Collapse
|
34
|
Kendler DL, Palacios S, Cox DA, Stock J, Alam J, Dowsett SA, Zanchetta J. Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis. Osteoporos Int 2012; 23:1091-101. [PMID: 21374068 DOI: 10.1007/s00198-011-1587-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2010] [Accepted: 01/26/2011] [Indexed: 11/26/2022]
Abstract
UNLABELLED Arzoxifene increased bone mineral density and decreased bone turnover to a significantly greater extent than raloxifene. The hot flush incidence was lower with arzoxifene than raloxifene. INTRODUCTION To assess the effect of arzoxifene versus raloxifene on change in lumbar spine (LS) bone mineral density (BMD) in postmenopausal women with osteoporosis. METHODS In this 12-month study (NEXT trial), participants were randomly assigned to arzoxifene 20 mg/day (N = 158) or raloxifene 60 mg/day (N = 162). All received daily calcium and vitamin D. Change in LS BMD was assessed by DXA. Secondary objectives included assessment of femoral neck (FN) and total hip BMD, serum bone turnover markers, and safety. RESULTS Treatment groups were similar at baseline (mean age 63 years, mean LS BMD T-score -2.9). At 12 months, the increase in LS BMD with arzoxifene was greater than with raloxifene (+2.75% vs. +1.66%), as was FN and total hip BMD (P < 0.05). For LS and FN, this effect was also evident at 6 months. Arzoxifene reduced bone turnover to a greater extent than raloxifene at 3, 6, and 12 months (P < 0.05). The proportion of women reporting ≥ 1 adverse event did not differ between treatment groups, nor did vaginal bleeding. No cases of endometrial polyps, hyperplasia, or cancer were reported. Nasopharyngitis and bronchitis were reported more frequently with arzoxifene versus raloxifene (10.1% vs. 2.5%, and 5.1% vs. 0%, respectively) and new/worsening hot flushes were reported less frequently with arzoxifene (7.0% vs. 16.7%) (P < 0.05). CONCLUSIONS Arzoxifene increased BMD and suppressed bone turnover to a greater extent than raloxifene and resulted in a lower incidence of new/worsening hot flushes. Based on subsequent findings from a fracture outcome study, this difference did not translate into improved fracture efficacy.
Collapse
Affiliation(s)
- D L Kendler
- University of British Columbia, 600-1285 West Broadway, Vancouver, BC, Canada V6H 3X8.
| | | | | | | | | | | | | |
Collapse
|
35
|
Vitko JR, Re RN, Alam J, Cook JL. Cell-penetrating peptides corresponding to the angiotensin II Type 1 receptor reduce receptor accumulation and cell surface expression and signaling. Am J Hypertens 2012; 25:24-8. [PMID: 21901015 DOI: 10.1038/ajh.2011.162] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Our previous published studies have established the γ-aminobutyric acid (GABA) receptor-associated protein (GABARAP) as a trafficking protein for the angiotensin II type 1A receptor (AT(1)R). GABARAP overexpression increases both AT(1)R protein accumulation and translocation to the plasma membrane. The present study examined the inhibitory effects of decoy peptides on receptor expression and plasma membrane accumulation. The decoy peptides correspond to the AT(1)R cytoplasmic domain located immediately proximal to the 7th transmembrane domain, a region implicated in GABARAP binding. This competitive binding study was designed as a first step toward evaluating the GABARAP:AT(1)R binding interface as a target for reducing AT(1)R trafficking to the plasma membrane. METHODS AT(1)R and GABARAP plasmids were transfected into mammalian cell lines simultaneously with cell-penetrating peptides (CPPs). CPP-1 and CPP-2 consist of the penetratin (pANT(43-58)) CPP with downstream fusions of GKKFKKYFLQL (AT(1)R) and GKKFEEAFLQL (AT(1)R-mutant) amino acids, respectively. CPP-3 consists of the HIV TAT(48-60) CPP with GKKFKKYFLQL (AT(1)R) fused downstream. Western blotting, signal transduction studies, and 3D deconvolution microscopy experiments were employed. RESULTS Immunoblot analyses and live cell deconvolution microscopy demonstrated that inhibitory (but not control) peptides completely blocked GABARAP-induced intracellular AT(1)R accumulation and cell surface accumulation. GABARAP also stimulated angiotensin II-mediated phospho-ERK1/2 induction by ~ fivefold. This activation was, similarly, quantitatively blocked by the inhibitory peptides. CONCLUSIONS Cell-penetrating decoy peptides which were designed to block the AT(1)R:GABARAP interaction, effectively reduced AT(1)R intracellular accumulation and cell-surface trafficking and signaling. The binding interaction site between AT(1)R and GABARAP represents a potential therapeutic target.
Collapse
|
36
|
. AAM, Sharifuzza A, Faruk M, Kader M, Alam J, Begum R, . HOR. Improved Citric Acid Production by Radiation Mutant Aspergillus niger Using Sugarcane Bagasse Extract. ACTA ACUST UNITED AC 2011. [DOI: 10.3923/biotech.2012.44.49] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
37
|
Chattopadhyay BP, Nandy A, Hossain M, Alam J. Pulmonary function status of Kolkata inhabitants of different economic class during rainy and winter seasons. J Environ Sci Eng 2011; 53:507-514. [PMID: 23505833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The pulmonary function status of the Kolkata inhabitants was evaluated during rainy and winter seasons. The pulmonary function tests (PFT) of the 1st study was carried out in the months of July to August when the environment is pollution free and the 2nd study was carried out between November to January when the environment is polluted. In the 1st study a total of 162 (male-88, female-74) inhabitants were investigated and again they were repeated in same way in the 2nd study. To evaluate the respiratory function status, Slow Vital Capacity (SVC), Forced Vital Capacity (FVC) and Peak Expiratory Flow Rate (PEFR) were recorded. Forced expiratory volume in one second (FEV1), forced expiratory volume in 1 sec as the percentage of FVC (FEV1%), forced expiratory flow at 200mL-1200 mL, 25-75% and 75-85% were calculated from the same tracings. Males were having higher mean PFT values compared to females because of sex difference. In the 2nd study PFT values were significantly lower compared to 1st study. According to different durations of stay category the PFT values were significantly reduced in winter season. The regression lines showed decrement as the duration of stay on that area was increased and it was more in 2nd study compared to 1st study. In both studies the PFT values found higher in high economic class of people. Between the same economic class of people PFT values were significantly lower in winter season. Respiratory impairments were also found higher during winter and males were having more impairment compared to females. Respiratory impairments in both sexes were more in winter and low economic class of people had maximum respiratory impairments. In rainy season and winter season the respiratory impairments were less in non-smokers. Males had more respiratory function impairments compared to females.
Collapse
Affiliation(s)
- B P Chattopadhyay
- Regional Occupational Health Centre (Eastern), Indian Council of Medical Research, Block-DP, Sector-V, Salt Lake City, Kolkata-700 091
| | | | | | | |
Collapse
|
38
|
Knappett PSK, Escamilla V, Layton A, McKay LD, Emch M, Williams DE, Huq R, Alam J, Farhana L, Mailloux BJ, Ferguson A, Sayler GS, Ahmed KM, van Geen A. Impact of population and latrines on fecal contamination of ponds in rural Bangladesh. Sci Total Environ 2011; 409:3174-82. [PMID: 21632095 PMCID: PMC3150537 DOI: 10.1016/j.scitotenv.2011.04.043] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2010] [Revised: 04/07/2011] [Accepted: 04/25/2011] [Indexed: 04/14/2023]
Abstract
A majority of households in Bangladesh rely on pond water for hygiene. Exposure to pond water fecal contamination could therefore still contribute to diarrheal disease despite the installation of numerous tubewells for drinking. The objectives of this study are to determine the predominant sources (human or livestock) of fecal pollution in ponds and examine the association between local population, latrine density, latrine quality and concentrations of fecal bacteria and pathogens in pond water. Forty-three ponds were analyzed for E. coli using culture-based methods and E. coli, Bacteroidales and adenovirus using quantitative PCR. Population and sanitation spatial data were collected and measured against pond fecal contamination. Humans were the dominant source of fecal contamination in 79% of the ponds according to Bacteroidales measurements. Ponds directly receiving latrine effluent had the highest concentrations of fecal indicator bacteria (up to 10⁶ Most Probable Number (MPN) of culturable E. coli per 100 mL). Concentrations of fecal indicator bacteria correlated with population surveyed within a distance of 30-70 m (p<0.05) and total latrines surveyed within 50-70 m (p<0.05). Unsanitary latrines (visible effluent or open pits) within the pond drainage basin were also significantly correlated to fecal indicator concentrations (p<0.05). Water in the vast majority of the surveyed ponds contained unsafe levels of fecal contamination attributable primarily to unsanitary latrines, and to lesser extent, to sanitary latrines and cattle. Since the majority of fecal pollution is derived from human waste, continued use of pond water could help explain the persistence of diarrheal disease in rural South Asia.
Collapse
Affiliation(s)
- Peter S K Knappett
- Department of Earth and Planetary Sciences, The University of Tennessee, Knoxville, TN 37996-1410, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
We describe a 90-year-old woman with right upper limb monoparesis secondary to varicella zoster virus infection as a result of extensive inflammatory involvement of the entire brachial plexus at root level. To our knowledge, this is the first report of entire brachial plexus involvement in a living patient of such advanced age. Despite a delay in presentation and thus initiation of treatment, a favourable clinical response was observed.
Collapse
Affiliation(s)
- S Bilal
- Department of Internal Medicine, Louth County Hospital, Dundalk, Ireland.
| | | | | | | | | |
Collapse
|
40
|
Chattopadhyay BP, Mukherjee AK, Gangopadhyay PK, Alam J, Roychowdhury A. Respiratory effect related to exposure of different concentrations of arsenic in drinking water in West Bengal, India. J Environ Sci Eng 2010; 52:147-154. [PMID: 21114123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Arsenic toxicity due to drinking of arsenic contaminated water has been one of the worst environmental health hazards. High levels of arsenic have been reported in different natural water sources from West Bengal for more than two decades. Groundwater contamination by arsenic and its adverse effects on the health of a big population in nine districts of West Bengal have been reported. The problems found were mainly related to skin and respiratory, digestive, cardiovascular and nervous systems. The respiratory effects are largely confined to those who had the skin lesion. The present study was undertaken to evaluate the respiratory effects of exposure to different levels of arsenic in drinking water. The water samples were collected from different tube wells and wells in the study area. Analysis of arsenic was done by Atomic Absorption Spectrophotometer with hydride generation system. Based on the consumption of arsenic concentrations in drinking water the populations were divided into three categories, i.e., <=50 microg/L, >50 - <= 150 microg/L and >150 microg/L. Standard techniques of medical examination were applied to elicit signs and recorded in the pre-designed proforma. A written consent was taken from each subject for their voluntary participation in the study. 112 subjects were investigated. The respiratory effect was evaluated by measuring the pulmonary function test (PFT). Vital Capacity (VC) and Forced Vital Capacity (FVC) were measured by Spirovit-SP-10 (Schiller Health Care Pvt Ltd., Switzerland) and Peak Expiratory Flow Rate by Wrights Peak Flow Meter (Clement and Clarke, UK). The PFT values showed gradual decrement among the males following skin pigmentation, keratosis and arsenicosis. The respiratory function impairment among the male subjects found as restrictive type (26.41%), obstructive type (3.77%) and combined type (7.54%), whereas in females only the restrictive type of impairment (10.16%) was found. Restrictive type of impairments among the subjects increased as the concentration of arsenic in drinking water increased, in males 15.78%, 29.41% and 35.29% and in females 4.54%, 5.00% and 23.52% respectively. The pathophysiologic mechanism, by which ingested arsenic leads to impairments of lung function and increased respiratory symptoms, is yet to be understood and needs further investigation.
Collapse
Affiliation(s)
- B P Chattopadhyay
- Regional Occupational Health Centre (Eastern), Indian Council of Medical Research, Block DP, Sector-V, Salt Lake City, Kolkata, India.
| | | | | | | | | |
Collapse
|
41
|
Bolognese M, Krege JH, Utian WH, Feldman R, Broy S, Meats DL, Alam J, Lakshmanan M, Omizo M. Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass. J Clin Endocrinol Metab 2009; 94:2284-9. [PMID: 19351734 DOI: 10.1210/jc.2008-2143] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
INTRODUCTION Arzoxifene, a benzothiophene estrogen agonist/antagonist, is being developed for prevention and treatment of osteoporosis and for risk reduction of invasive breast cancer in postmenopausal women. METHODS The effects of arzoxifene 20 mg/d on bone mineral density (BMD), uterine safety, and overall safety were studied in the FOUNDATION study, a 2-yr randomized, placebo-controlled trial including 331 postmenopausal women with normal to low bone mass. RESULTS Compared to placebo, arzoxifene significantly increased lumbar spine (+2.9%) and total hip (+2.2%) BMD. Arzoxifene decreased biochemical markers of bone metabolism compared to placebo. Changes in breast density were neutral or slightly decreased in the arzoxifene vs. placebo group. There was no evidence of endometrial hyperplasia or carcinoma in the arzoxifene group as assessed by central review of baseline and follow-up endometrial biopsies. There was no significant change between the groups in endometrial thickness assessed by transvaginal ultrasound. The incidence of uterine polyps and vaginal bleeding was not significantly different between the groups. Vulvovaginal mycotic infection was the only adverse event significantly increased in the arzoxifene vs. placebo group. Hot flushes were not significantly different between the groups. CONCLUSION In postmenopausal women with normal to low bone mass, arzoxifene 20 mg/d increased BMD at the spine and hip and had a neutral effect on the uterus and endometrium.
Collapse
Affiliation(s)
- M Bolognese
- Bethesda Health Research Center, Bone Health Center of Bethesda, Maryland 20892, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Utian W, Krege J, Bolognese M, Feldman R, Broy S, Meats D, Alam J, Lakshmanan M, Omizo M. ARZOXIFENE IN POSTMENOPAUSAL WOMEN WITH NORMAL OR LOW BONE MASS. Maturitas 2009. [DOI: 10.1016/s0378-5122(09)70360-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
43
|
Kabir SE, Alam J, Ghosh S, Kundu K, Hogarth G, Tocher DA, Hossain GMG, Roesky HW. Synthesis, structure and reactivity of tetranuclear square-type complexes of rhenium and manganese bearing pyrimidine-2-thiolate (pymS) ligands: versatile and efficient precursors for mono- and polynuclear compounds containing M(CO)3 (M = Re, Mn) fragments. Dalton Trans 2009:4458-67. [DOI: 10.1039/b815337j] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
44
|
Thimmulappa RK, Rangasamy T, Alam J, Biswal S. Dibenzoylmethane activates Nrf2-dependent detoxification pathway and inhibits benzo(a)pyrene induced DNA adducts in lungs. Med Chem 2008; 4:473-81. [PMID: 18782044 DOI: 10.2174/157340608785700199] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Cigarette smoke derived carcinogens have been identified as the main agents implicated in lung carcinogenesis. Epidemiological as well as animal studies have indicated that certain phytochemicals can block the carcinogenic process by enhancing the detoxification of environmental and or dietary carcinogens. Dibenzoylmethane (DBM), a minor constituent of licorice, is a beta-ketone analog of curcumin, a promising chemopreventive agent for colon, breast and skin cancer. The present study was designed to examine the chemopreventive efficacy of DBM in lungs, its global molecular targets and the mechanism of its action. Feeding DBM to A/J mice significantly inhibited benzo[a]pyrene induced DNA adducts in lungs. Further analysis of its global molecular targets in lungs by oligonucleotide microarray revealed expression of several cytoprotective genes including phase II enzymes that are regulated by Nrf2, a basic leucine zipper transcription factor. To decipher if DBM mediates its function via Nrf2 activation, Nrf2 dependent reporter assays were performed. DBM elicited a dose-dependent increase in antioxidant response element (ARE)-driven luciferase reporter activity which correlated with an increase in mRNA expression of NQO1, GSTA2, and GCLC in mouse hepatoma cells, which are well established targets of Nrf2. Conversely, DBM stimulated ARE reporter activity was attenuated by a dominant-negative mutant of Nrf2. Electrophoretic mobility shift assay confirmed that DBM greatly increased the DNA binding activity of Nrf2. In conclusion, DBM mediates the induction of phase II enzymes by Nrf2 activation and inhibits benzo[a]pyrene induced DNA adducts by enhancing its detoxification in lungs.
Collapse
Affiliation(s)
- R K Thimmulappa
- Bloomberg School of Public Health, Johns Hopkins University, Department of Environmental Health Sciences, Baltimore, MD 21205-2179, USA
| | | | | | | |
Collapse
|
45
|
Chattopadhyay BP, Saiyed HN, Roychowdhury A, Alam J. Pulmonary function in aluminium smelter and surrounding community--a case study. J Environ Sci Eng 2007; 49:309-316. [PMID: 18476380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The increase of industrial activities in the Angul-Talcher area, Orissa resulted in indiscriminate disposal of waste into the environment leading to the deterioration of the quality of the environment, which affects the health of the workers as well as the community people. Considering the magnitude of the problem, the pulmonary function study had been carried out in one of the largest aluminium producing plant of the country as well as surrounding community people. Aluminium is produced from oxides of alumina by Hall-Heroult smelting process. The electrolysis called as aluminium smelting is carried out in an electrolytic cell (pot) having anode, cathode and electrolyte. The aluminium is deposited in the cathode and the oxygen moves towards anode is released. The workers working at the captive power plant (CPP), which is necessary to meet the power demand of the smelter plant were also investigated. 180 smelter plants workers (non-smoker 129, smoker-51) of different sections and 37 captive power plant workers (non-smoker 29, smoker-8) had undergone pulmonary function tests. Besides these, 85 persons from the surrounding community (non-smoker-66, smoker-19) were also investigated. The workers were all male. Spirometric assessments of Vital Capacity (VC), Forced Vital Capacity (FVC), and Peak Expiratory Flow Rate (PEFR) were done by Spirovit-sp-10 (Schiller Health Care Ltd, Switzerland) and Wrights Peak flow meter (Clement and Clarke, UK). Different lung volumes like FEV1, FEV1%, and flow rates like FEF200-1200ml, FEF25-75% and FEF75-85% were calculated from the same tracings pulmonary function test (PFT) results of the workers according to different age groups, duration of exposures and smoking habits. The mean values of SVC, FVC and FEV1 of smelter plant workers were found higher compared to the community people but the values of captive power plant workers were very much close to the values of the community people. A gradual decrement of the PFT values was found as duration of exposure increased. Lung volumes and the flow rates were decreased as age increases but in some age groups that trend was not followed. It has been found that in each category of subjects, smokers have the higher mean pulmonary function values compared to the non-smokers. Except the community people in all other cases the different flow rates were found higher in nonsmokers compared to smokers. The restrictive, obstructive and combined restrictive and obstructive types of impairments among the subjects were noticed. The respiratory impairment among the workers as a whole was found higher in smelter plant workers (9.44%) followed by the captive power plant workers (5.40%) and the community people (2.35%). In smelter plant workers both the restrictive and obstructive impairments were found higher compared to captive power plant and the community people.
Collapse
Affiliation(s)
- B P Chattopadhyay
- Regional Occupational Health Centre (Eastern), Indian Council of Medical Research, Respiratory Physiology Division, Block-DP, Sec-V, Salt Lake City, Kolkata
| | | | | | | |
Collapse
|
46
|
Deepa M, Ahmad S, Sood K, Alam J, Ahmad S, Srivastava A. Electrochromic properties of polyaniline thin film nanostructures derived from solutions of ionic liquid/polyethylene glycol. Electrochim Acta 2007. [DOI: 10.1016/j.electacta.2007.06.031] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
47
|
Chattopadhyay BP, Mahata A, Kundu S, Alam J, Das S, Roychowdhury A. A study on blood eosinophil level and ventilatory pulmonary function of the workers exposed to storage grain dust. Indian J Occup Environ Med 2007; 11:21-5. [PMID: 21957368 PMCID: PMC3168107 DOI: 10.4103/0019-5278.32460] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The workers engaged in storage grain handling are exposed to storage grain dust and suffer from different respiratory symptoms like, cough wheezing, chest tightness, eye and nasal irritations. It has been reported abroad and the present study results noted that the grain handlers have allergic symptoms like redness of eyes, itching, sneezing, skin rash, breathlessness and decrement of pulmonary function test values. According to their nature of job, the workers of storage grain godowns were divided into four categories i.e., load handling worker (LHW), ancillary, quality control and depot administration workers. The pulmonary function tests (PFT) and the differential count of leucocytes were carried out among the workers by standard technique. Decrement of pulmonary function test values was noted with the increment of blood eosinophil level. The PFT results were presented according to the blood eosinophil level. The decrement of mean PFT values were noticed as the blood level of eosinophil gradually increased from, up to -4%, >4-10% and above 10%. The maximum numbers of workers in different job categories are belonged to >4 -10% of eosinophil level. The percentage figure of workers in different departments were LHW 48.38%, (n=45), ancillary 38.88%, (n=7), quality control 54.54% (n=6) and depot administration workers 47.05% (n=16) are belonged to that range. Among the total workers the higher figure was found >4-10% ranges 47.43% (n=74) workers. The allergic manifestations like redness, itchiness and watering of eyes, sneezing, cough, breathless etc. are reported. These workers have blood eosinophil level and low pulmonary function test values. The respiratory impairments among the workers are restrictive, obstructive and combined restrictive and obstructive type.
Collapse
|
48
|
Alam J, Noor Mohammad S. Doping induced surface chemistry dictating the characteristics of Schottky contacts to III-V nitride semiconductors. J Chem Phys 2006; 125:44718. [PMID: 16942185 DOI: 10.1063/1.2220563] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
While lightly doped semiconductors are preferred for Schottky contacts, heavily doped semiconductors are preferred for Ohmic contacts. The upper limit of doping for Schottky contacts and the lower limit of doping for Ohmic contacts have not, however, been quantified. To address this problem, the influence of doping induced surface chemistry on the electrical characteristics of Schottky diodes has been studied. Hall measurement, current-voltage measurements, and transmission electron microscopy have been performed. The most remarkable observation of the study is a relationship between the surface dislocation density and the ideality factor of the Schottky diodes. The observation leads to a conclusion that the upper limit of the semiconductor doping for Schottky diodes should be such that it leads to negligible barrier height reduction without the creation of excessive surface dislocation density.
Collapse
Affiliation(s)
- J Alam
- Materials Science Research Center of Excellence, Howard University, Washington, District of Columbia 20059, USA
| | | |
Collapse
|
49
|
Pischke SE, Zhou Z, Song R, Ning W, Alam J, Ryter SW, Choi AMK. Phosphatidylinositol 3-kinase/Akt pathway mediates heme oxygenase-1 regulation by lipopolysaccharide. Cell Mol Biol (Noisy-le-grand) 2005; 51:461-70. [PMID: 16309568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2004] [Accepted: 07/01/2005] [Indexed: 05/05/2023]
Abstract
The stress-inducible protein heme oxygenase-1 exerts potent antiinflammatory, antiapoptotic and cytoprotective effects in vitro and in vivo. Another important mediator of cytoprotection, the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway activates many proteins involved in the maintenance of cellular homeostasis. Since activation of heme oxygenase-1 and PI3K/Akt both protect the cellular environment, we postulated that PI3K/Akt can regulate the induction of heme oxygenase-1 by proinflammatory stress. The treatment of primary murine macrophage cells (RAW 264.7) with lipopolysaccharide induced heme oxygenase-1 protein and mRNA expression, and increased the phosphorylation of Akt and p38 mitogen activated protein kinase (p38 MAPK). These cellular effects of lipopolysaccharide were markedly diminished by pre-treatment with wortmannin, a specific inhibitor of PI3K. Furthermore, lipopolysaccharide-inducible heme oxygenase expression was blocked by SB203580, a specific inhibitor of p38 MAPK. Both wortmannin and SB203580 decreased lipopolysaccharide-inducible NF-E2-related factor (Nrf2) DNA binding activity. Transfection of macrophages with dominant negative mutants of PI3K, Akt and Nrf2, as well as wortmannin treatment, significantly reduced the transcriptional activity of a minimal heme oxygenase-1 promoter luciferase construct (D33HO-1luc). We demonstrate, to our knowledge for the first time, that upon proinflammatory stimulation heme oxygenase-1 gene expression in macrophages depends on PI3K/Akt and p38 MAPK acting upstream of Nrf2-dependent promoter activation.
Collapse
Affiliation(s)
- S E Pischke
- Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, MUH 628NW, Pittsburgh, Pennsylvania 15213, USA
| | | | | | | | | | | | | |
Collapse
|
50
|
Singh BR, Alam J, Hansda D. Alopecia induced by salmonellosis in guinea pigs. Vet Rec 2005; 156:516-8. [PMID: 15833970 DOI: 10.1136/vr.156.16.516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- B R Singh
- Division of Bacteriology and Mycology, National Salmonella Centre, Indian Veterinary Research Institute, Izatnagar 243122, India
| | | | | |
Collapse
|